戻る Agenda
Session 5: Penetrating the Market
Session Chair(s)
Juliana Marguerite Reed, MS
Executive Director, The Biosimilars Forum, United States
As the number of approved biosimilars in the US marketplace increases, understanding the perspectives and needs of the patient, payer, and prescriber are key requirements to ensure the successful uptake of biosimilars. This session will explore those perspectives and ways to address the needs of these important stakeholders.
Learning Objective : - Provide an overview of where biosimilars started in Europe and where they are today
- Provide an overview of lessons learned and recommendations in Europe
- Provide physician, patient, and payor/PBM perspectives on needs and requirements for the successful uptake of biosimilars.
- Provide an update on the FDA’s efforts to educate stakeholders on biosimilars
Speaker(s)
Suzette Kox, MPHARM
Senior Director International-Biosimilars Medicines Group, Medicines for Europe, Belgium
Speaker
Angus Worthing, MD
Chair, Government Affairs Committee, American College of Rheumatology, United States
Speaker
Leah Howard, JD
Vice President, Government Relations and Advocacy , National Psoriasis Foundation, United States
Speaker
Chris Davis
Director, Government Affairs, Express Scripts, United States
Speaker
Ms. Sarah Ikenberry
Associate Director, Stakeholder Engagement and Education, OTBB, CDER, US FDA, United States
Speaker
Cheryl Schwartz
General Manager, US Biosimilars, Pfizer, Inc., United States
Speaker
Tânia Teixeira, PHARMD
EMA Official at the FDA, European Medicines Agency, United States
Speaker